Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
03:29
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
FAQs
   
Discussion forum - 13th International Conference on Malignant Lymphoma
    Topic - CLL

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
 

Poster: 184
Visits: 118
Title: Results of a Phase II randomizing intensified rituximab pre-phase followed by standard FCR vs standard FCR in previously untreated patients with Active B-CLL.
Authors: Stephane Lepretre ,
Centre: Frenhc Intergrope On CLL and WM

You must be registered to reply or comment.

RESULTS OF A PHASE II RANDOMIZING INTENSIFIED RITUXIMAB PRE-PHASE FOLLOWED BY STANDARD FCR VS STANDARD FCR IN PREVIOUSLY UNTREATED PATIENTS WITH ACTIVE B-CLL.

Stephane Lepretre
Thread initiator
Subspeciality
Reg: 5/27/2015 12:31:00 PM
Comment# 1
Rituximab dosing regimen is largely empirical in CLL patients and phase I study has suggested a dose response relationship in previously treated CLL patients. Pharmacokinetics data from REACH study, randomising FCR and FC for relapsed/refractory CLL, showed a correlation between rituximab exposure evaluated by AUC and Cthrough and clinical response. Pharmacokinetics analyses showed a faster clearance (CL2) of rituximab in CLL patients compared to non-Hodgkins lymphoma patients. We purposed to intensify rituximab regimen before the first course of FCR in order to improve rituximab exposure and increase response rate in untreated, medically fit CLL patients.

Comment added on 5/27/2015 12:31:00 PM 
     
You must be registered to reply or comment.



Most viewed poster for this congress
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center

Poster most viewed in this topic
Poster: 169
Visits: 178
Title: Chronic Lymphocytic Leukemia B-cells are rescued from apoptosis by extracellular vesicles from bone marrow mesenchymal stromal cells
Authors: Emerence Crompot ,
Centre: LTCC


 




PosterSessionOnline
Logo Draft
 
Logo Cert